Compare iShares MSCI South Korea ETF (EWY) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs Heron Therapeutics Inc — how do they compare? iShares MSCI South Korea ETF trades at $178.26 (market cap $26.25B), while Heron Therapeutics Inc trades at $0.36 (market cap $68.01M). The key difference: iShares MSCI South Korea ETF is far larger — about 386× Heron Therapeutics Inc's market cap, and iShares MSCI South Korea ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Korea ETF for 46 Days and Heron Therapeutics Inc for 35 Days on average.
| EWY | HRTX | |
|---|---|---|
Market Cap | $26.25B | $68.01M |
Volume | 19,056,075 | 1,891,941 |
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $1.49 |
52-Week Low | $80.72 | $0.27 |
Typical Hold Time | 46 Days | 35 Days |
Enterprise Value | — | $174.75M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY, the iShares MSCI South Korea ETF, trades at $183.72, down 1.44% amid mixed technical signals and KOSPI volatility driven by semiconductor sector sensitivity. The ETF shows neutral momentum with bullish moving averages but faces resistance near $185. Recent news highlights South Korea's strong 2026 market performance and AI-driven semiconductor demand, though concerns persist about high oil prices and rising US yields impacting tech valuations.
Outlook remains cautiously optimistic given EWY's heavy concentration in Samsung and SK hynix, which benefit from AI memory cycle strength. Key risks include reliance on two stocks, geopolitical tensions, and macroeconomic pressures. The ETF offers exposure to South Korea's tech-led growth but requires monitoring of memory cycle trends and foreign investor flows.
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
